Advanced Drug Delivery Reviews

Article	Citations
Leveraging the neurosurgical operating room for therapeutic development in NeuroOncology	644
Editorial board members	598
Emerging antibiotic alternatives: From antimicrobial peptides to bacteriophage therapies	358
Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity	283
MIDD in Japan– Implementations, challenges and opportunities	279
Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies	278
Opportunities and challenges in delivering biologics for Alzheimer’s disease by low-intensity ultrasound	275
Recent advances in endocrine organoids for therapeutic application	238
Drug delivery for metabolism targeted cancer immunotherapy	235
Deciphering albumin-directed drug delivery by imaging	228
Bacterially mediated drug delivery and therapeutics: Strategies and advancements	226
Agony of choice: How anesthetics affect the composition and function of extracellular vesicles	220
Gene editing strategies to treat lysosomal disorders: The example of mucopolysaccharidoses	199
Therapeutic and delivery strategies of phytoconstituents for renal fibrosis	198
Penetration and translocation of functional inorganic nanomaterials into biological barriers	184
Liposomal formulations for treating lysosomal storage disorders	180
Nanoparticle-neutrophils interactions for autoimmune regulation	179
Design, development and clinical translation of CriPec®-based core-crosslinked polymeric micelles	171
Recent applications of electrical, centrifugal, and pressurised emerging technologies for fibrous structure engineering in drug delivery, regenerative medicine and theranostics	163
Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders	153
Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond	150
Tools for computational design and high-throughput screening of therapeutic enzymes	149
Models to study basic and applied aspects of lysosomal storage disorders	149
Long-acting inhaled medicines: Present and future	144
Progress on the pathological tissue microenvironment barrier-modulated nanomedicine	139

MicroRNAs and their delivery in diabetic fibrosis	137
Luminescent quantum dots: Synthesis, optical properties, bioimaging and toxicity	137
Cell membrane-coated nanoparticles for targeting carcinogenic bacteria	137
Nanovaccines with cell-derived components for cancer immunotherapy	136
Integrating microneedles and sensing strategies for diagnostic and monitoring applications: The state of the art	136
Biopharmaceutical drug delivery and phototherapy using protein crystals	130
Editorial/Preface	129
Ultrasonic particles: An approach for targeted gene delivery	128
Emerging Voices in Drug Delivery – Harnessing and Modulating Complex Biological Systems (Issue 2)	128
Targeting microbiome, drug metabolism, and drug delivery in oncology	128
Phytonanomaterials as therapeutic agents and drug delivery carriers	126
Editorial Board	125
Novel strategies for modulating the gut microbiome for cancer therapy	123
In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols	123
Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics	123
Exosome- and extracellular vesicle-based approaches for the treatment of lysosomal storage disorders	122
From cells to subcellular organelles: Next-generation cancer therapy based on peptide self-assembly	121
Synthetic biology-guided design and biosynthesis of protein polymers for delivery	121
Activatable dual-functional molecular agents for imaging-guided cancer therapy	121
Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer’s disease	120
Physical methods for enhancing drug absorption from the gastrointestinal tract	119
Nanoparticles-mediated ion channels manipulation: From their membrane interactions to bioapplications	118
Solid implantable devices for sustained drug delivery	117
RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer	116
Activatable fluorescent probes for real-time imaging-guided tumor therapy	116
Drug delivery using gold nanoparticles	115
In situ cellular hitchhiking of nanoparticles for drug delivery	112
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers	112
Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems	112
Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases	111
Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches	111
Role of extracellular vesicles in liver diseases and their therapeutic potential	111
Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery	110
3D printing of drug delivery systems enhanced with micro/nano-technology	109
Strategies to develop polymeric microneedles for controlled drug release	109
Model-informed precision dosing: State of the art and future perspectives	107
Micro-patterned cell populations as advanced pharmaceutical drugs with precise functional control	107
Lysosomal therapies and drug delivery strategies: An overview	107
Drug delivery strategies for management of women’s health issues in the upper genital tract	106
Hurdles in translating science from lab to market in delivery systems for Cosmetics: An industrial perspective	106
Novel drug delivery systems for the management of dry eye	105
Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers	102
High-throughput proteomics and AI for cancer biomarker discovery	102
Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer	102
Miniaturized therapeutic systems for ultrasound-modulated drug delivery to the central and peripheral nervous system	101
Technological and translational challenges for extracellular vesicle in therapy and diagnosis	100
Nanosensitizer-mediated unique dynamic therapy tactics for effective inhibition of deep tumors	100
Soft nano and microstructures for the photomodulation of cellular signaling and behavior	98
In-vitro 3D modelling for charged particle therapy – Uncertainties and opportunities	97
The extracellular matrix of hematopoietic stem cell niches	96

Emerging drug delivery systems with traditional routes – A roadmap to chronic inflammatory diseases	95
Modular design principle based on compartmental drug delivery systems	95
Light sheet fluorescence microscopy for monitoring drug delivery: Unlocking the developmental phases of embryos	94
Advances in photoactivated carbon-based nanostructured materials for targeted cancer therapy	93
Nanobodies: Robust miniprotein binders in biomedicine	92
Tumour extravasation of nanomedicine: The EPR and alternative pathways	92
Extracellular vesicles for tissue repair and regeneration: Evidence, challenges and opportunities	90
Unignored intracellular journey and biomedical applications of extracellular vesicles	89
Engineering complexity in human tissue models of cancer	89
Fit and forget: The future of dental implant therapy via nanotechnology	88
Editorial board members	87
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives	87
Preface: Image-assisted organoid research and application	86
Editorial board members	86
Corrigendum to ‘Cell-penetrating peptides in protein mimicry and cancer therapeutics’ [Advanced Drug Delivery Reviews, 180 (2022), 114044]	86
Editorial board members	86
Corrigendum to “Editorial: Advanced strategies to bridge the gap between inflammation and tissue regeneration” [Adv. Drug Deliv. Rev. 209 (2024) 115328]	86
Implications and pitfalls for cancer diagnostics exploiting extracellular vesicles	85
Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and clinical evidence of safety and efficacy	85
Beyond the adverse effects of the systemic route: Exploiting nanocarriers for the topical treatment of skin cancers	85
Optical clearing of tissues: Issues of antimicrobial phototherapy and drug delivery	83
Design of disintegrable nanoassemblies to release multiple small-sized nanoparticles	82
Listening to drug delivery and responses via photoacoustic imaging	82
Nanoparticles for local delivery of siRNA in lung therapy	81
Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory	81
MicroRNA-targeting nanomedicines for the treatment of intervertebral disc degeneration	81
Exosomes as natural delivery carriers for programmable therapeutic nucleic acid nanoparticles (NANPs)	81
Women-specific routes of administration for drugs: A critical overview	81
Engineering and loading therapeutic extracellular vesicles for clinical translation: A data reporting frame for comparability	81
Harnessing inhaled nanoparticles to overcome the pulmonary barrier for respiratory disease therapy	80
Recent progress in upconversion nanomaterials for emerging optical biological applications	80
Nanomedicine from amphiphilized prodrugs: Concept and clinical translation	80
Modulating tumor physical microenvironment for fueling CAR-T cell therapy	79
Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment	79
Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease	78
Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders	78
Dynamic nanoassembly-based drug delivery system (DNDDS): Learning from nature	78
Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy	78
Nanoparticle-based immunotherapeutics: From the properties of nanocores to the differential effects of administration routes	78
Reversibility and therapeutic development for neurodevelopmental disorders, insights from genetic animal models	77
Can microorganisms develop resistance against light based anti-infective agents?	77
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond	76
Storming the gate: New approaches for targeting the dynamic tight junction for improved drug delivery	75
Omics approaches for the assessment of biological responses to nanoparticles	74
Editorial: Subcellular organelle-targeting of nanomaterials for enhancing therapeutic effectiveness	73
Spectral computed tomography with inorganic nanomaterials: State-of-the-art	73
Additive manufacturing in spatial patterning for spinal cord injury treatment	73
Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins	73
Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19	73
Of devices and drugs – Ingestible bots for diagnosis and therapy	72
Editorial Board	72
Applications of pharmacometrics in drug development	72
Progress of engineered bacteria for tumor therapy	72
Corrigendum to “Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials” [Adv. Drug Delivery Rev. 192 (2023) 114636]	72
Clinical translation of advanced colonic drug delivery technologies	72
Dynamic nano-assemblies based on two-dimensional inorganic nanoparticles: Construction and preclinical demonstration	71
Imaging drug delivery to the lungs: Methods and applications in oncology	71
Nanomedicines for the topical treatment of vulvovaginal infections: Addressing the challenges of antimicrobial resistance	71
Intranasal and inhaled delivery systems for targeting circadian dysfunction in neurodegenerative disorders, perspective and future outlook	69
The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development	69
Synthetic polypeptides for drug and gene delivery, and tissue engineering	69
Engineering of stimuli-responsive self-assembled biomimetic nanoparticles	69
Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics	69
3D extrusion bioprinting of microbial inks for biomedical applications	69
Engineering stromal heterogeneity in cancer	69
Protein corona: Friend or foe? Co-opting serum proteins for nanoparticle delivery	68
Intrathecal delivery and its applications in leptomeningeal disease	68
Steric stabilization of bioactive nanoparticles using elastin-like polypeptides	68
Advances in Salmonella Typhimurium-based drug delivery system for cancer therapy	68
Towards controlled drug delivery in brain tumors with microbubble-enhanced focused ultrasound	68
Microbiota and plant-derived vesicles that serve as therapeutic agents and delivery carriers to regulate metabolic syndrome	67
Cell-penetrating peptides in protein mimicry and cancer therapeutics	67
Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy	67
Recent developments in lactose blend formulations for carrier-based dry powder inhalation	66
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment	66
Delivery and kinetics of immersion optical clearing agents in tissues: Optical imaging from ex vivo to in vivo	65
Editorial board members	65
Nanoarchitectured two-dimensional layered double hydroxides-based nanocomposites for biomedical applications	65
Special Issue (SI) on: Emerging pharmaceutical technologies (From advanced materials & formulations to new processes) for novel dosage development	65
Adherence to minimal experimental requirements for defining extracellular vesicles and their functions	65

Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics	65
The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives	65
Microbubble-assisted ultrasound for inner ear drug delivery	64
Corrigendum to “Light sheet fluorescence microscopy for monitoring drug delivery: unlocking the developmental phases of embryos” [Adv Drug Del. Rev. 218 (2025) 115520]	64
Delivery of synthetic mRNAs for tissue regeneration	63
Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors – An update	63
Revealing the clinical potential of high-resolution organoids	63
Progress of tumor-resident intracellular bacteria for cancer therapy	62
Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations	62
Non-spherical micro- and nanoparticles for drug delivery: Progress over 15 years	62
Corrigendum to “Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic” [Adv. Drug Delivery Rev. 179 (2021) 114000]	62
Laser ablation: Heating up the anti-tumor response in the intracranial compartment	61
Sustained delivery approaches to improving adaptive immune responses	61
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics	61
Microneedle-Mediated Vaccination: Innovation and Translation	60
Biosafety of mesoporous silica nanoparticles; towards clinical translation	60
Merging data curation and machine learning to improve nanomedicines	60
Biomaterial-based delivery of nucleic acids for tissue regeneration	60
The tendon microenvironment: Engineered in vitro models to study cellular crosstalk	59
Towards artificial intelligence-enabled extracellular vesicle precision drug delivery	58
Biomaterials releasing drug responsively to promote wound healing via regulation of pathological microenvironment	58
Advances in solid formulation of pharmaceutical biologics	58
The importance of pre-formulation studies and of 3D-printed nasal casts in the success of a pharmaceutical product intended for nose-to-brain delivery	58
Ocular therapies with biomacromolecules: From local injection to eyedrop and emerging noninvasive delivery strategies	58
Editorial board members	57
Editorial board members	57
Editorial board members	57
Editorial board members	57
Editorial board members	57
Integrated pharmacokinetic-pharmacodynamic and agent-based modelling in drug development: Current status and future perspectives	57
Editorial Board	56
Theme issue: In vitro mucus models	56
Next generation concepts in dermal delivery, theranostics, and preclinical testing	56
Drugging the lymphatic system: An emerging opportunity for cancer immunotherapy	56
Editorial Board	56
Targeting bacterial metabolites in tumor for cancer therapy: An alternative approach for targeting tumor-associated bacteria	55
Targeted delivery methods for RNA interference are necessary to obtain a potential functional cure for HIV/AIDS	55
Advances in long-acting injectables, implants, and vaginal rings for contraception and HIV prevention	55
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits	55
Cell-based relay delivery strategy in biomedical applications	55
Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles	55
From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer	54
Leveraging advances in immunopathology and artificial intelligence to analyze in vitro tumor models in composition and space	54
Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation	53
Mesoporous silica nanoparticles for pulmonary drug delivery	53
Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health	53
Fungal infections: Immune defense, immunotherapies and vaccines	53
Photonic and magnetic materials for on-demand local drug delivery	52
Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids	52
Recent applications of three-dimensional bioprinting in drug discovery and development	52
The effects of protein corona on in vivo fate of nanocarriers	52
Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic	52
Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment	51
Biomedical engineering of two-dimensional MXenes	51
Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor	51
Precise subcellular targeting approaches for organelle-related disorders	51
The RNA-binding protein HuR in human cancer: A friend or foe?	51
Biological and intracellular fates of drug nanocrystals through different delivery routes: Recent development enabled by bioimaging and PK modeling	51
Advances on colorectal cancer 3D models: The needed translational technology for nanomedicine screening	50
Transdermal drug delivery via microneedles to mediate wound microenvironment	50
The role of the HBCU pipeline in diversifying the STEM workforce: Training the next generation of drug delivery researchers	50
Advances in modular control of CAR-T therapy with adapter-mediated CARs	50
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems	50
Stealth and pseudo-stealth nanocarriers	50
Long-acting parenteral drug delivery systems for the treatment of chronic diseases	50
Current issues in optical monitoring of drug delivery via hair follicles	50
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics	49
Mitochondrial endogenous substance transport-inspired nanomaterials for mitochondria-targeted gene delivery	49
Defensins: The natural peptide antibiotic	49
Translating a radiolabeled imaging agent to the clinic	49
Characterization of dry powder inhaler performance through experimental methods	49
Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity	49
Editorial Board	49
Navigating the landscape of RNA delivery systems in cardiovascular disease therapeutics	49
Purified mucins in drug delivery research	49